CGRP-targeted antibodies in difficult-to-treat migraine
Abstract
A new study shows that the monoclonal antibody fremanezumab is effective for migraine prophylaxis, even in patients who have failed to respond to multiple preventive treatments. However, not all patients benefit from this treatment, and detailed investigation of non-responders could help to identify additional pharmacological targets and increase the number of...
Paper Details
Title
CGRP-targeted antibodies in difficult-to-treat migraine
Published Date
Oct 8, 2019
Journal
Volume
15
Issue
12
Pages
688 - 689
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History